General | LivaNova PLC

Skip to main navigation

Careers
Contact Us

About Us
News & Events
- Press Releases
- Events & Presentations
Investors
Therapeutic Areas

code

General

LivaNova to Announce First-Quarter 2026 Results

Read more about LivaNova to Announce First-Quarter 2026 Results

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

Read more about LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

Read more about LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

LivaNova to Present at J.P. Morgan Healthcare Conference in January

Read more about LivaNova to Present at J.P. Morgan Healthcare Conference in January

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

Read more about LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

Read more about LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

LivaNova to Present at Piper Sandler Healthcare Conference in December

Read more about LivaNova to Present at Piper Sandler Healthcare Conference in December

LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

Read more about LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

Read more about LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

LivaNova to Present at Wolfe Research Healthcare Conference in November

Read more about LivaNova to Present at Wolfe Research Healthcare Conference in November

Pagination

Page 1
Next page

Subscribe to General

Our Company

About Us
News

Therapeutic Areas

Cardiopulmonary
Drug-Resistant Epilepsy
Difficult-to-Treat Depression

Contact Us

Customer Service
Commercial Sponsorship
Donations and Grants
Investigator-Initiated Research

Transparency

Modern Slavery Statement
Carbon Reduction Plan
Conflict Minerals

© 2026 LivaNova PLC
Careers
Investors
Terms of Use
Privacy Policy
Washington Nevada Consumer Health Data
Cybersecurity
Patents
Cookie Policy
Cookie Settings

LivaNova PLC - Registered in England and Wales - Registered No. 09451374 - 20 Eastbourne Terrace, London, W2 6LG, United Kingdom